The estimated Net Worth of Raj Kannan is at least $6.93 Milion dollars as of 23 November 2020. Mr. Kannan owns over 120,000 units of Chiasma Inc stock worth over $515,477 and over the last 5 years he sold CHMA stock worth over $0. In addition, he makes $6,413,280 as Chief Executive Officer a Director at Chiasma Inc.
Raj has made over 2 trades of the Chiasma Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 120,000 units of CHMA stock worth $480,000 on 23 November 2020.
The largest trade he's ever made was buying 120,000 units of Chiasma Inc stock on 23 November 2020 worth over $480,000. On average, Raj trades about 14,444 units every 15 days since 2019. As of 23 November 2020 he still owns at least 137,095 units of Chiasma Inc stock.
You can see the complete history of Mr. Kannan stock trades at the bottom of the page.
Raj Kannan is Chief Executive Officer, Director of the Company. He became our Chief Executive Officer and joined our Board of Directors on June 17, 2019. Mr. Kannan joined our company from Kiniksa Pharmaceuticals, Ltd. (“Kiniksa”) (NASDAQ: KNSA) where he worked since July 2018 as Chief Commercial Officer. In that role, he was responsible for building and leading the company’s commercial operations, including sales, marketing, business analytics, and market access functions. Prior to Kiniksa, Mr. Kannan served as the Global Head of the Neurology and Immunology (“N&I”) business franchise at Merck KGaA, where he was responsible for $2 billion in annual revenues. In that role, he successfully led the launch of Mavenclad, an oral small molecule in multiple sclerosis. He also chaired the N&I franchise leadership team that was responsible for advancing the immunology pipeline assets, prioritizing the portfolio mix, and allocating resources across development assets. Prior to Merck KGaA, Mr. Kannan spent ten years at Boehringer Ingelheim (“Boehringer”) in roles of increasing responsibility in the U.S., Canada, and in Germany, including the role of Global Marketing Head of the Cardiovascular Franchise where he was responsible for over $3.5 billion in annual revenues. Before Boehringer, he worked for almost ten years at Merck and Co. in various roles from field sales to senior marketing manager in the U.S. Mr. Kannan has led or supported multiple successful launches across therapeutic areas both in the U.S. and globally. Mr. Kannan received a B.S. in chemistry from the University of Madras, as well as an M.B.A. from East Carolina University.
As the Chief Executive Officer a Director of Chiasma Inc, the total compensation of Raj Kannan at Chiasma Inc is $6,413,280. There are no executives at Chiasma Inc getting paid more.
Raj Kannan is 56, he's been the Chief Executive Officer a Director of Chiasma Inc since 2019. There are 5 older and 7 younger executives at Chiasma Inc. The oldest executive at Chiasma Inc is John Scarlett, 69, who is the Independent Director.
Raj's mailing address filed with the SEC is C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM, NC, 27703.
Over the last 9 years, insiders at Chiasma Inc have traded over $0 worth of Chiasma Inc stock and bought 324,855 units worth $2,372,906 . The most active insiders traders include Llp Abingworth, Ansbert Gadicke a John F Thero. On average, Chiasma Inc executives and independent directors trade stock every 85 days with the average trade being worth of $94,895. The most recent stock trade was executed by Roni Mamluk on 9 February 2021, trading 27,981 units of CHMA stock currently worth $51,765.
Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In June 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analog approved by the FDA, is available for commercial sale. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma.
Chiasma Inc executives and other stock owners filed with the SEC include: